Plain-English translation of NCT07371663 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a research study testing a new medication called TCC1727 combined with other cancer-fighting drugs (such as benmelstobart, olaparib, or topotecan) in patients with advanced solid cancers. The trial is divided into two stages: first, researchers will find the right dose of the medication that is safe and effective; then, they will test whether this combination works well in specific cancer types like lung cancer, stomach cancer, endometrial cancer, and melanoma.
Many patients with advanced solid tumors run out of standard treatment options or don't respond well to existing therapies. This medication is being tested to see if combining it with other cancer drugs could offer a new, more effective treatment option for people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will take the new medication as a tablet by mouth twice per day in 21-day cycles, sometimes combined with an intravenous infusion (a medicine given through your vein) depending on which treatment group you join. The trial has two phases: in the first phase, researchers test different doses to find the safest and most effective level; in the second phase, they test how well the medication works in specific cancer types. You will continue treatment as long as your cancer does not progress and you tolerate the medication well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China